==== Front BMC Neurol BMC Neurol BMC Neurology 1471-2377 BioMed Central London 3299 10.1186/s12883-023-03299-z Case Report Clinical characteristics of Leucine-rich glioma-inactivated protein 1 antibody-mediated autoimmune encephalitis in a 6-year-old girl: case report and literature reviews Chen Liqing Su Tangfeng http://orcid.org/0000-0001-7449-5913 Liu Yan lyan3022@163.com grid.412793.a 0000 0004 1799 5032 Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 30 6 2023 30 6 2023 2023 23 25319 10 2022 16 6 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Background Autoimmune encephalitis related to the leucine-rich glioma-inactivated protein 1(LGI1) antibody is the most prevalent in older adults, manifesting as seizures, faciobrachial dystonic seizures (FBDS), cognitive impairment, memory disturbance, hyponatremia and neuropsychiatric disorders. However the data pertaining to children affected by the disease is still limited. Case presentation and literature reviews This study presents a detailed report of a 6-year-old Chinese girl who experienced nose aches and faciobrachial dystonic seizures (FBDS). Electrolyte testing revealed that she had hyponatremia and brain MRI showed an abnormality in the left temporal pole. Additionally, anti-LGI1 antibodies were detected in both her serum (1:100) and CSF (1:30). The patient was treated with immunotherapy and symptom management, which proved effective. Furthermore, we provide a summary of 25 pediatric cases of anti-LGI1 encephalitis. Pediatric patients rarely exhibited FBDS and hyponatremia, and some cases presented with isolated syndromes. But the therapeutic outcomes of pediatric patients were generally good. Conclusions In this report, we describe a patient who developed a rare symptom of nose aches possibly as one of symptoms of anti-LGI1 encephalitis, which highlights the possibility of atypical symptoms in children that may be misdiagnosed. Reviewing the literature, the clinical features differed between pediatric and adult cases. Therefore, it is crucial to collect and analyze data from more cases to promote accurate diagnosis and timely treatment. Keywords LGI1 Autoimmune encephalitis Seizures Pediatric Case report issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2023 ==== Body pmcBackground The initial report on autoimmune encephalitis related to the LGI1 antibody was published by Lai et al in 2010 [1]. Anti-LGI1 encephalitis is considered the second most common form of autoimmune encephalitis observed in adults with an average onset age of around 63 years and a higher incidence in males [2, 3]. The main clinical features of anti-LGI1 encephalitis are seizures, particularly faciobrachial dystonic seizures (FBDS), cognitive impairment, memory disturbance, hyponatremia and neuropsychiatric disorders [4]. Reports on pediatric anti-LGI1 encephalitis are rare. Lopez-Chiriboga et al. examined neurological autoimmunity of LGI1 and contactin-associated protein like-2 (CASPR2) in 264 voltage gated potassium channel (VGKC) complex IgG seropositive pediatric patients and found that only 2% of patients tested positive for LGI-IgG [5]. The rarity of anti-LGI1 encephalitis in pediatric patients may be related to a lower expression of LGI1 protein in younger individuals as observed in mice [6]. We present the case of a 6-year-old Chinese girl who was diagnosed with anti-LGI1 encephalitis which was characterized by seizures and hyponatremia. Additionally, we conducted an analysis to summarize the clinical features of previously reported cases of pediatric anti-LGI1 encephalitis. Case presentation Our hospital’s emergency department admitted a previously healthy 6-year-old Chinese girl who was experiencing recurrent seizures. The patient had no family history of seizures or any other neurological disorders. The patient began experiencing intermittent nose aches one month ago. She experienced nose aches once every 2-3 days, which subsided after approximately 10 seconds each time. Initially, she received a diagnosis of rhinitis and was prescribed mometasone furoate at another hospital. This treatment appeared to initially reduce the frequency of nose ache, but it worsened again half a month ago, occurring as frequently as 1-2 times per day. A week ago, she also developed a cough and was promptly given oral anti-cough and anti-inflammatory medication, which led to significant improvement. A few hours prior to admission, the patient experienced frequent seizures characterized by a tonic twitch of her right upper arm, accompanied by a frightened facial expression and frequent head shaking. Each seizure episode lasted only a few seconds. The patient experienced seizures at a frequency of approximately 10-20 times per day, but did not lose consciousness during these episodes. The patient did not present any psycho-behavioral changes, sleep disorders, cognitive impairment, or other related symptoms. Our neurological examination did not reveal any positive signs or obvious abnormalities. After conducting a video electroencephalogram (VEEG) that showed epileptiform activity in the left frontotemporal region (Fig. 1), Perampanel was prescribed at a dosage of 2mg per day. This led to a reduction in her seizures about two days following the commencement of the treatment. However, she continued to experience nose aches once or twice per day. A brain magnetic resonance imaging (MRI) was conducted on the patient, and the result revealed an increased signal in the left temporal pole on T2FLAIR (Fig. 2 AB). The laboratory examinations, including a complete blood count, liver and renal function tests and electrolyte and metabolic tests, showed normal results. The initial serum sodium level was measured at 138.2mmo/L. The cell count, glucose, protein and chloride levels in the cerebrospinal fluid (CSF) sample were all within normal limits. The initial sodium level in CSF was 146.7mmol/L and no pathogens growth was observed in the sample. The cell-based indirect immunofluorescence antibody assay was utilized to evaluate the presence of antibodies for autoimmune encephalitis in the serum and CSF samples. This approach revealed the existence of Anti-LGI1 antibodies in both the serum (1:100) and CSF (1:30) (Fig. 3 AB). Other series of autoimmune encephalitis antibody were detected to be negative in serum and CSF. In addition, tests for tumor maker and paraneoplastic neuronal antibody showed a negative result. Computed Tomography (CT) scans of the chest and thymus also showed a negative result.Fig. 1 Video electroencephalogram recordings before the treatment: fast wave rhythm→ slow wave rhythm at the left frontal-temporal electrodes, evolved to the left hemisphere. The whole procedure lasted for 20-25 seconds. Moreover, a tonic twitch of the right upper arm, associated with scared facial expression and frequent head shaking were observed clinically (lasting for 20-25 seconds) Fig. 2 The results of brain MRI. A, B Brain MRI showed increased signal in the left temporal pole before treatment. C, D Brain MRI showed increased signal in the left temporal pole after intravenous immunoglobulin and corticosteroids therapy. Picture A was compared with picture C, the high signal slightly decreased and the edema slightly subsided in the left temporal pole (the white arrow) on T2FLAIR. Picture B was compared with picture D, the temporal horn (the white arrow) was enlarged in the picture D. It indicated that edema subsided after treatment Fig. 3 The levels of anti-LGI1 antibody were measured in both serum and CSF before treatment. A The cell-based assay for CSF anti-LGI1 antibody showed a positive result with a titer of 1:30. B The cell-based assay for serum anti-LGI1 antibody showed a positive result with a titer of 1:100. C Negative control. D Scale bar: 20um The patient found immediate relief from the tonic twitch in her right upper arm after taking 2mg/day of Perampanel. However, she continued to experience nose aches 2-7 times a day. The dosage of Perampanel was gradually increased up to 6mg/day. The patient also received intravenous immunoglobulin (IVIG, 2g/kg) and methylprednisolone pulse therapy (20mg/kg.d for 3 days, 10mg/kg.d for 3 days, 5mg/kg.d for 3 days). The patient was subsequently prescribed oral prednisolone, starting at 2mg/kg.d for 2 weeks and then reducing 2 tablets every 2 weeks. Unfortunately, this treatment did not yield any significant benefits. After one month of undergoing a treatment regimen consisting of Perampanel, IVIG and corticosteroids, the patient’s VEEG, brain MRI and anti-LGI1 antibodies were re-evaluated. The results of the VEEG (Fig. 4) revealed a slow wave in the left temporal region, accompanied by a sharp slow wave during the onset of nose ache. The brain MRI showed a minor reduction in edema in the left temporal pole (Fig. 2 CD). The titers of the anti-LGI1 antibody decreased in both the serum (1:30) and the CSF (1:10). Afterward, the patient received another IVIG (2g/kg) infusion and lacosamide (2mg/kg.d) was added to the treatment regime. Although the frequency of nose aches decreased slightly (2-3 times/day), the patient started experiencing dizziness and headaches. Unfortunately, after a week, the frequency of nose aches increased again and was observed to occur between 3-7 times per day. Throughout the patient’s treatment, regular complete blood count, liver and renal function, and electrolyte tests were conducted. The serum sodium level was found to be 133mmol/L. We escalated therapy with mycophenolate mofetil (MMF, 25mg/kg.d). As a result, her nose ache disappeared (Fig. 5). The patient continues to be closely monitored and has not experienced a recurrence of her symptoms.Fig. 4 Video electroencephalogram recordings after one month of treatment: slow wave and sharp slow wave in left temporal region, lasting for 20 seconds. At the same time, the patient complained of nasal pain, lasting for about 20 seconds Fig. 5 A timeline figure of symptoms and treatment. The black line on the graph represents the frequency of a tonic twitch of the patient’s right upper arm. The blue line on the graph represents the frequency of nose aches. The dotted line on the graph represents the timeline of medication usage. MPS is used as 20mg/kg.d for 3 days, 10mg/kg.d for 3 days, 5mg/kg.d for 3 days. PER: Perampanel; IVIG: Intravenous Immune Globulin; MPS: Methylprednisolone; Pred: Prednisone; LCM: Lacpsamide; MMF: Mycophenolate Mofetil Literature review of pediatric patients with anti-LGI1 encephalitis A literature search was conducted on Pubmed, CNKI, WOS and WanFang (until June 2023), using the search terms ‘children or pediatric’ and ‘leucine-rich glioma inactivated 1 or LGI1’. Following a careful review of the literature, we identified 15 articles describing 24 pediatric patients (<18 years) with anti-LGI1 encephalitis [5, 7–20]. Our patient was included as the 25th participant in the study. The twenty-five cases described included 15 females and 10males. The median age of onset is 9.84, ranging from 2 to 17 years. The clinical characteristics of these pediatric patients with anti-LGI1 encephalitis are summarized in Tables 1 and 2. The prominent clinical manifestations include seizures, encephalopathy, psycho-behavioral changes, movement disorders. Only 4 patients had FBDS [15, 17, 20] and 3 patients had hyponatremia [15, 18] which are commonly encountered in adult LGI1-IgG-positive patients. While frequent seizures, encephalopathy and psycho-behavioral changes are common neurological accompaniments of anti-LGI1 encephalitis in pediatric patients, it is worth noting that some patients just present with isolated symptoms, such as movement disorders, sleep disorders, seizures, or cerebellar ataxia.Table 1 The clinical characteristics of 25 patients Pt/Sex/ Age of onset Clinical features EEG Brain MRI/PET Treatment Outcome Ref 1/M/6y Movement disorders Normal Normal Pimozide, tetrabenazine CS, IVIG Recovered Erer Özbek S et al (2015) [7] 2/F/8y Encephalopathy, seizures, psycho-behavioral changes Epileptiform discharge MRI: hyperintense lesions in the right hippocampal region LEV CS, IVIG Recovered Incecik F et al (2016) [9] 3/F/7y Psycho-behavioral changes, encephalopathy, sleep disorders, movement disorders Background slowing Normal - CS, IVIG Recovered AlHakeem AS et al (2016) [8] 4/M/14y Psycho-behavioral changes, amnesia, seizures Normal MRI: swelling of the left hippocampus - CS, PE, MMF Improved Schimmel M et al (2018) [10] 5/M/9y Encephalopathy, seizures, dizzy, psycho-behavioral changes Epileptiform discharge MRI: Brainstem: T2 hyperintensity without enhancement - IVIG Improved López-Chiriboga AS et al (2018) [5] 6/F/17y Encephalopathy, sleep disorders, pain, ANS - Normal - IVIG Improved López-Chiriboga AS et al (2018) [5] 7/F/17y Encephalopathy, seizures Epileptiform discharge Normal - IVIG, Aza Improved López-Chiriboga AS et al (2018) [5] 8/F/5y Encephalopathy, seizures, psycho-behavioral changes Epileptiform discharge Normal VPA, LCM - Seizures cessation López-Chiriboga AS et al (2018) [5] 9/M/13y Encephalopathy, amnesia, seizures, pain, psycho-behavioral changes Normal MRI: Left limbic T2 hyperintensities - IVIG, CS Improved López-Chiriboga AS et al (2018) [5] 10/F/17y Weight loss, pain, ANS Normal N/A Symptomatic - N/A López-Chiriboga AS et al (2018) [5] 11/F/14y Dizzy, pain, psycho-behavioral changes Normal Normal Symptomatic - Stable López-Chiriboga AS et al (2018) [5] 12/F/7y Seizures (including FBDS), encephalopathy, hyponatremia, amnesia Epileptiform discharge PET: subtle hypometabolism in the right temporal and bilateral parietal cortices LEV, VPA, CBZ, midazolam, TP, PB, PHT, LCM; TPM CS, IVIG, R-FC Relapsed Mir A et al (2019) [11] Alotaibi W (2022) [15] 13/M/8y Sleep disorder Focal slow waves MRI: left hippocampal lesions - IVIG Improved Zhang J et al (2019) [12] 14/M/15y Seizures Focal slow waves and epileptic form discharge Normal LEV, IVIG Recovered Zhang J et al (2019) [12] 15/F/14y Sleep disorders, movement disorders, psycho-behavioral changes N/A Normal N/A N/A N/A Giannoccaro MP et al (2021) [13] 16/F/4y Seizures, encephalopathy, sleep disorders, psycho-behavioral changes epileptiform discharge normal LEV, CZP, OXC; IVIG, CS Recovered Luo J et al (2021) [14] 17/F/7y Seizures Background slowing and epileptiform discharge normal OXC IVIG, CS Recovered Wang Y et al (2022) [16] 18/M/2y Cerebellar ataxia normal normal - CS Recovered Weihua Z et al (2022) [17] 19/M/4y Cerebellar ataxia, seizures (including FBDS), encephalopathy Background slowing PET: significantly increased metabolism in bilateral basal ganglia and mildly increased in the medial temporal lobes LEV, CZP IVIG, CS Recovered Weihua Z et al (2022) [17] 20/F/14y Movement disorders, ataxia, dysarthria, psycho-behavioral changes, hyponatremia, normal MRI: hyperintensities in the left frontal cortex, right medial temporal lobe, left insula and corpus striatum, right inferior frontal region, and left temporal lobe LEV CS, IVIG Improved Özçifçi G et al (2022) [18] 21/F/11y Seizures Background slowing and epileptiform discharge normal OXC IVIG Recovered Wang Y et al (2023) [19] 22/M/4y Seizures, psycho-behavioral changes Background slowing and epileptiform discharge MRI: mild atrophy on the cortex of left hemisphere VPA, OXC, LCM IVIG, CS, RTX, CLB Improved Wang Y et al (2023) [19] 23/M/17y Seizures Background slowing and epileptiform discharge normal VPA, OXC IVIG, CS Recovered Wang Y et al (2023) [19] 24/F/6y Seizures (including FBDS), movement disorders, ataxia, psycho-behavioral changes, amnesia Focal slow and sharp waves MRI: T2 and FLAIR high signal intensity in the left anterior putamen and right caudate nucleus PB, OXC, VPA, LTG CS, IVIG, RTX, TCZ Improved Jang S et al (2023) [20] 25/F/6y Seizures (including FBDS), hyponatremia Epileptiform discharge MRI: an increased signal in the left temporal pole on T2FLAIR PER, LCM IVIG, CS, MMF Recovered This study Pt patient, M male, F female, y year, EEG electroencephalogram, MRI magnetic resonance imaging, PET positron emission tomography, LEV levetiracetam, CS corticosteroid, IVIG intravenous immunoglobulin, PE plasma exchange, MMF mycophenolate mofetil, ANS automatic nervous system, Aza Azathioprine, VPA valproicacid, LCM lacosamide, N/A not available, FBDS faciobrachial dystonic seizures, CBZ carbamazepine, TP thiopental, PB phenobarbitone, PHT phenytoin, TPM topiramate, RTX rituximab, CZP clonazepam, OXC oxcarbazepine, CLB clonazepam, TCZ Tocilizumab, LTG lamotrigine, PER Perampanel Table 2 Main data in the patients (including our patient) with anti-LGI1 encephalitis Clinical features LGI-positive encephalitis (n=25) Seizures 16/25 (64%) Encephalopathy 10/25 (40%) Psycho-behavioral changes 12/25 (48%) Sleep disorders 5/25 (20%) Pain 4/25 (16%) Amnesia 4/25 (16%) Movement disorders 6/25 (24%) FBDS 4/25 (16%) Hyponatremia 3/25 (12%) Ataxia 4/25 (16%) ANS 2/25 (8%) Dizzy 2/25 (8%) Abnormal brain MRI/PET 11/25 (44%) Abnormal EEG 15/25 (60%) Immune therapy 20/25 (80%) LGI1 Leucine-rich glioma-inactivated protein 1, FBDS faciobrachial dystonic seizures, ANS automatic nervous system, EEG electroencephalogram, MRI magnetic resonance imaging, PET positron emission tomography Brain MRIs or positron emission tomographies (PETs) were available for 24 patients (one was not given) [5] and revealed abnormalities in 11 patients [5, 9–12, 17–20]: brainstem hyperintensities (1 case) [5], mild atrophy on the cortex of left hemisphere (1 case) [19], bilateral basal ganglia (2 cases) [17, 20], limbic lobe (temporal lobe or hippocampus) hyperintensities (7 cases) [5, 9–12, 18]. Of the 23 patients for whom response and outcome data were available, 20 patients received immunotherapy (intravenous immunoglobulin, corticosteroid, plasmapheresis, azathioprine, mycophenolate mofetil, rituximab, tocilizumab) [5, 7–20], while 3 patients received only symptomatic therapy [5]. Both types of therapy were found to be beneficial, resulting in full recovery for 11 patients [7, 9, 12, 14, 16, 17, 19]. One patient initially responded well to first-line immunotherapy with corticosteroids, IVIG but suffered a relapse after 7 months. He did not fully recover until he underwent treatment with rituximab [15]. Discussion and conclusions According to the Chinese expert consensus on the diagnosis of autoimmune encephalitis, anti-LGI1 encephalitis can be diagnosed using the following criteria: acute or subacute onset with progressive aggravation; clinical signs of limbic encephalitis or FBDS; normal leukocyte count or mild lymphocyte reaction on CSF examination; abnormal brain MRI signals in the bilateral or unilateral medial temporal lobe; abnormal EEG activity; and serum and/or CSF anti-LGIl antibody positivity. Our case presented with an acute onset of seizure, a normal leukocyte count on CSF examination, and abnormal brain MRI signals in the unilateral temporal lobe. These symptoms, combined with the abnormal EEG findings and positive anti-LGIl antibody in the serum and CSF, supported the diagnosis of anti-LGI1 encephalitis. LGI1 is a secreted neuronal protein that interacts with the presynaptic protein, a disintegrin and metalloproteinase 23 (ADAM23); and the postsynaptic protein, a disintegrin and metalloproteinase 22 (ADAM22). These interactions lead to the organization of a trans-synaptic protein complex that involves pre-synaptic Kv1.1/Kv1.2 potassium channels and post-synaptic AMPAR scaffolds [21]. LGI1 is mainly present in the hippocampus and temporal cortex [22]. According to previous reports, in LGI1 IgG-positive cases, most patients’ brain MRI or PET showed lesions in mesial temporal lobe [23]. In this pediatric cohort, about 44% of patients revealed abnormalities in Brain MRIs or PETs, with lesions primarily in the temporal lobe or hippocampus, which is similar to the adult patients. In our case, the patient’s brain MRI showed an abnormality in the left temporal pole, leading to suspicion of limbic encephalitis. An antineuronal antibody test was performed on both serum and CSF. All patients had LGI1-IgG in their serum or/and CSF in this pediatric cohort. Importantly, pediatric cases appear to show distinctly different clinical presentations compared to adult patients. For example, men were more commonly affected than women (66% were men) [24]. In contrast, among the pediatric patients described, we observed a greater prevalence of females (60%) than males (40%) in pediatric patients. In adult patients, FBDS and hyponatremia were typically identified as hallmark symptoms [25], but only 4 patients had FBDS [15, 17, 20] and 3 patients had hyponatremia in our cohort [15, 18]. Frequent seizures, encephalopathy, psycho-behavioral changes were the most common neurological accompaniments of anti-LGI1 encephalitis in our pediatric patients. Indeed, focal seizures were found to be more common than FBDS. However, at times, it can be challenging to differentiate between FBDS and focal-onset seizures. Three patients with hyponatremia were reported [15, 18], which differed from the patients described in the original articles [5]. The absence of apparent cancer was consistent with previously reported cases of pediatric patients [5, 26]. In addition, isolated symptoms may be observed in some pediatric patients with anti-LGI1 encephalitis, which can make it challenging to identify certain clinical presentations such as neuropathic pain or memory disorders, particularly in very young patients. Diagnosing anti-LGI1 encephalitis early based on clinical features alone can be challenging in young patients. The therapeutic strategies used in pediatric patients generally led to positive outcomes [5, 7–20]. Three patients received only symptomatic therapy [5]. According to previous reports, the natural history of anti-LGI1 encephalitis was variable, and spontaneous complete recovery may occur without immune therapy in adult patients [26]. This pattern has also been observed in pediatric patients [5]. Nosadini et al. [26] also found no correlation between time to immune therapy and positive outcomes, and patients who received second-line immune therapy had a higher relapse rate than patients treated with first-line immune therapy only in adult patients. However, this has not been reported in pediatric patients and needs to be confirmed by more cases. In conclusion, the characteristics of anti-LGI1 encephalitis in children differs from those in adults. However, the reports about pediatric LGI1-antibody encephalitis are rare. It is crucial to collect and analyze data from more cases to promote accurate diagnosis and timely treatment. Abbreviations LGI1 Leucine-rich glioma-inactivated protein 1 FBDS Faciobrachial dystonic seizures MRI Magnetic resonance imaging VGKC Voltage gated potassium channel CASPR2 Contactin-associated protein like-2 VEEG Electroencephalogram CSF Cerebrospinal fluid CT Computed Tomography MMF Mycophenolate mofetil PET Positron Emission Tomography IVIG Intravenous immunoglobulin ADAM23 A disintegrin and metalloproteinase 23 ADAM22 A disintegrin and metalloproteinase 22 AMPA α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid Acknowledgements We would like to thank the patient and her parents for their support in this study. Authors’ contributions LC drafted the manuscript and attended the patient. YL did the follow-up with the patient. LC and YL edited the manuscript. TS commented on the video EEG (VEEG) graph. All authors contributed to the article and approved the submitted version. Funding No funding. Availability of data and materials The raw datasets generated and analyzed during the current study are not publicly available in order to protect participant confidentiality. The datasets obtained during the current study are available from the corresponding author if the requirements are reasonable. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. All study procedures were conducted in accordance with the tenets of the Declaration of Helsinki. The patient and her parents provided written informed consent to participate in this study. Consent for publication Written informed consent to publish this case was obtained from the patient and her parents, including case description and medical data. Completing interests All authors declare that they have no conflict of interest. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ==== Refs References 1. Lai M Huijbers MG Lancaster E Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series Lancet Neurol. 2010 9 8 776 785 10.1016/S1474-4422(10)70137-X 20580615 2. Dalmau J Geis C Graus F Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System Physiol Rev. 2017 97 2 839 887 10.1152/physrev.00010.2016 28298428 3. Li W Wu S Meng Q Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study BMC Neurol. 2018 18 1 96 10.1186/s12883-018-1099-z 29980179 4. Bing-Lei W Jia-Hua Z Yan L Three cases of antibody-LGI1 limbic encephalitis and review of literature Int J Neurosci. 2019 129 7 642 648 10.1080/00207454.2018.1512985 30112956 5. López-Chiriboga AS Klein C Zekeridou A LGI1 and CASPR2 neurological autoimmunity in children Ann Neurol. 2018 84 3 473 480 10.1002/ana.25310 30076629 6. Ribeiro PA Sbragia L Gilioli R Expression profile of Lgi1 gene in mouse brain during development J Mol Neurosci. 2008 35 3 323 329 10.1007/s12031-008-9096-0 18563303 7. Erer Özbek S Yapıcı Z Tüzün E A case of hyperkinetic movement disorder associated with LGI1 antibodies Turk J Pediatr. 2015 57 5 514 517 27411421 8. AlHakeem AS Mekki MS AlShahwan SM Acute psychosis in children: do not miss immune-mediated causes Neurosciences J. 2016 21 3 252 255 10.17712/nsj.2016.3.20150760 9. Incecik F Hergüner OM Besen S Limbic encephalitis associated with anti-leucine-rich glioma-inactivated-1 protein antibodies in a child Neurol India. 2016 64 6 1321 1323 10.4103/0028-3886.193776 27841212 10. Schimmel M Frühwald MC Bien CG Limbic encephalitis with LGI1 antibodies in a 14-year-old boy Eur J Paediatr Neurol. 2018 22 1 190 193 10.1016/j.ejpn.2017.08.004 28919330 11. Mir A Thani Z Bashir S LGI-1 antibody encephalitis in a seven-year-old girl Epileptic Disord. 2019 21 6 591 597 31871009 12. Zhang J Ji T Chen Q Pediatric Autoimmune Encephalitis: Case Series From Two Chinese Tertiary Pediatric Neurology Centers Front Neurol. 2019 10 906 10.3389/fneur.2019.00906 31507515 13. Giannoccaro MP, Pizza F, Jacobson L, et al. Neuronal surface antibodies are common in children with narcolepsy and active movement disorders. J Neurol Neurosurg Psychiatry. 2021:92(1):111–2. 14. Luo J Shi J Chen Y Leucine-rich glioma-inactivated protein 1 antibody-mediated autoimmune encephalitis in a 4-year-old girl: a case report Acta Epileptologica. 2021 3 4 10.1186/s42494-021-00039-z 15. Alotaibi W, Bashir S, Mir A. Faciobrachial Dystonic Seizures as a Sign of Relapse in a Child with LGI-1 Encephalitis. Child Neurol Open. 2022;9:2329048X221105960. 16. Wang Y Zhang WH Wang Y Case Report: Isolated Epileptic Seizures Associated With Anti-LGI1 Antibodies in a 7-Year-Old Girl With Literature Review Front Pediatr. 2022 10 856775 10.3389/fped.2022.856775 35712617 17. Weihua Z Haitao R Jie D Autoimmune cerebellar ataxia associated with anti-leucine-rich glioma-inactivated protein 1 antibodies: Two pediatric cases J Neuroimmunol. 2022 370 577918 10.1016/j.jneuroim.2022.577918 35853356 18. Özçifçi G Kamaşak T Keskin DB A rare case of antileucine-rich glioma-inactivated 1 encephalitis in a 14-year-old girl Turk J Pediatr. 2022 64 3 566 570 10.24953/turkjped.2021.1066 35899570 19. Wang Y Zhang D Tong L Anti-LGI1 encephalitis with initiating symptom of seizures in children Front Neurosci. 2023 17 1151430 10.3389/fnins.2023.1151430 37179544 20. Jang S Kim SY Kim WJ Chae JH Kim KJ Lim BC A case of pediatric anti-leucine-rich glioma inactivated 1 encephalitis with faciobrachial dystonic seizure Brain Dev. 2023 45 6 348 353 10.1016/j.braindev.2023.02.003 36858863 21. Lancaster E Martinez-Hernandez E Dalmau J Encephalitis and antibodies to synaptic and neuronal cell surface proteins Neurology. 2011 77 2 179 189 10.1212/WNL.0b013e318224afde 21747075 22. Van Sonderen A Petit-Pedrol M Dalmau J The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis Nat Rev Neurol. 2017 13 5 290 301 10.1038/nrneurol.2017.43 28418022 23. Vives-Rodriguez A Sivaraju A Louis ED Drop attacks: A clinical manifestation of LGI1 encephalitis Neurol Clin Pract. 2017 7 5 442 443 10.1212/CPJ.0000000000000390 29620086 24. Van Sonderen A Thijs RD Coenders EC Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up Neurology. 2016 87 14 1449 1456 10.1212/WNL.0000000000003173 27590293 25. Gadoth A Pittock SJ Dubey D Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients Ann Neurol. 2017 82 1 79 92 10.1002/ana.24979 28628235 26. Nosadini M Toldo I Tascini B LGI1 and CASPR2 autoimmunity in children: Systematic literature review and report of a young girl with Morvan syndrome J Neuroimmunol. 2019 335 577008 10.1016/j.jneuroim.2019.577008 31352183